Sanuwave Health, Inc. (SNWV) — SEC Filings
Sanuwave Health, Inc. (SNWV) — 50 SEC filings. Latest: 10-K (Mar 26, 2026). Includes 35 8-K, 6 10-Q, 2 10-K.
View Sanuwave Health, Inc. on SEC EDGAR
Overview
Sanuwave Health, Inc. (SNWV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: SANUWAVE Health, Inc. (SNWV) reported total revenues of $44.1 million for the fiscal year ended December 31, 2025, marking a significant 35% increase from $32.6 million in 2024. UltraMIST systems and consumables accounted for approximately 99% of 2025 revenues, up from 98% in 2024, with consumables
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 47 neutral, 3 mixed. The dominant filing sentiment for Sanuwave Health, Inc. is neutral.
Filing Type Overview
Sanuwave Health, Inc. (SNWV) has filed 2 10-K, 35 8-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 1 S-1, 1 SC 13G/A, 2 SC 13D/A with the SEC between May 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SNWV's 49 recent filings, 1 were flagged as high-risk, 31 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $44.1 million |
Key Executives
- Morgan Frank
- Gregory Bazar
- Jeffrey Blizard
- Ian Miller
- James Tyler
- Dr. Michael L. R. Smith
- Kevin Richardson
- David L. Johnson
- Morgan C. Frank
- James E. Besser
Industry Context
SANUWAVE operates in the large and growing U.S. wound care market, estimated at $67 billion. This market is driven by an aging population and the increasing prevalence of chronic diseases like diabetes, which lead to more complex wounds. The company's regenerative medicine approach using non-invasive ultrasound positions it within a segment focused on improving healing times and patient outcomes.
Top Tags
management-change (9) · financial-reporting (8) · operations (7) · financials (6) · filing (6) · corporate-governance (5) · 8-K (5) · board-of-directors (5) · financial-statements (4) · 10-Q (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $44.1M | 35% increase from $32.6 million in 2024, indicating strong sales growth for UltraMIST. |
| Revenue Growth | 35% | Year-over-year increase in total revenues from 2024 to 2025, highlighting market adoption. |
| UltraMIST Revenue Contribution | 99% | Percentage of total revenues from UltraMIST systems and consumables in 2025, showing product concentration. |
| Consumables Revenue Contribution | 58% | Percentage of total revenues from UltraMIST consumables in 2025, indicating a strong 'razor/razor blade' model. |
| Active UltraMIST Systems | 1,292 | Number of active systems in the field as of December 31, 2025, reflecting customer base. |
| Market Value of Non-Affiliate Common Stock | $233.3M | As of June 30, 2025, indicating a significant portion of the company's market capitalization. |
| Shares Outstanding | 8,594,209 | As of March 24, 2026, providing context for per-share metrics. |
| Patents | 60+ | Number of issued or pending patents worldwide as of December 31, 2025, protecting its technology. |
| Net Income (Q3 2025) | $10.325M | Significant swing from -$20.657M net loss in Q3 2024. |
| Revenue (9 months 2025) | $30.957M | Increased 38.8% from $22.308M in 9 months 2024. |
| Net Income (9 months 2025) | $5.704M | Turnaround from -$18.624M net loss in 9 months 2024. |
| Proceeds from Patent Sale | $5.000M | Contributed to cash flow from investing activities. |
| Gain on Derivative Liabilities (Q3 2025) | $6.097M | Major contributor to quarterly net income. |
| Proceeds from Secured Term Loan | $23.000M | Key component of debt refinancing in 9 months 2025. |
| Cash and Cash Equivalents (Sep 30, 2025) | $9.602M | Slight decrease from $10.237M at Dec 31, 2024. |
Frequently Asked Questions
What are the latest SEC filings for Sanuwave Health, Inc. (SNWV)?
Sanuwave Health, Inc. has 50 recent SEC filings from May 2024 to Mar 2026, including 35 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SNWV filings?
Across 50 filings, the sentiment breakdown is: 47 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Sanuwave Health, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sanuwave Health, Inc. (SNWV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sanuwave Health, Inc.?
Key financial highlights from Sanuwave Health, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SNWV?
The investment thesis for SNWV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sanuwave Health, Inc.?
Key executives identified across Sanuwave Health, Inc.'s filings include Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, James Tyler and 5 others.
What are the main risk factors for Sanuwave Health, Inc. stock?
Of SNWV's 49 assessed filings, 1 were flagged high-risk, 31 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Sanuwave Health, Inc.?
Forward guidance and predictions for Sanuwave Health, Inc. are extracted from SEC filings as they are enriched.